Table 1.
Cancer types represented in depression treatment research and the global burden of those cancers and cancers in comorbid depression populations
| Cancer type* | Research participants, n (%) |
Global cancer incidence† | Cancer cases (%) | Depression prevalence‡ | Comorbid depression incidence§ | Comorbid cases (%)¶ | Research participation per 100 000 comorbid cases |
| Bone, soft tissue | 53 (0.9) | 68 245 | 0.4 | 0.33 | 22 521 | 0.6 | 235 |
| Brain | 12 (0.2) | 266 745 | 1.5 | 0.28 | 74 689 | 2.1 | 16 |
| Breast | 2983 (49.5) | 2 088 035 | 11.7 | 0.20 | 417 607 | 11.8 | 714 |
| Digestive | 680 (11.2) | 4 965 321 | 27.9 | 0.27 | 1 340 637 | 37.7 | 51 |
| Endocrine | 18 (0.3) | 557 307 | 3.1 | 0.17 | 94 742 | 2.7 | 19 |
| Female genital | 375 (6.2) | 1 303 419 | 7.3 | 0.26 | 338 889 | 9.5 | 111 |
| Haematological | 295 (4.9) | 1 071 531 | 6.0 | 0.25 | 267 883 | 7.5 | 110 |
| Head and neck** | 343 (5.7) | 880 469 | 4.9 | 0.20 | 176 094 | 5.0 | 195 |
| Male genital | 89 (1.5) | 1 374 153 | 7.7 | 0.10 | 137 415 | 3.9 | 65 |
| Respiratory | 550 (9.1) | 2 092 686 | 11.8 | 0.21 | 439 464 | 12.4 | 125 |
| Skin | 40 (0.7) | 1 325 473 | 7.4 | 0.07 | 92 783 | 2.6 | 43 |
| Urinary tract | 189 (3.1) | 938 930 | 5.3 | 0.16 | 150 229 | 4.2 | 126 |
| Total†† | 5627 | 16 932 314 | 3 512 928 |
*Cancer types categorised according to ICD-11 where possible.
†GLOBOCAN global incidence data.
‡Estimated depression prevalence rates from cross-sectional study or meta-analysis.3 8–10
§Estimated from cancer incidence and depression prevalence within cancer types.
¶Estimated percentage of all cases of cancer comorbid with depression.
**Not an ICD-11 category, grouped according to clinical usage in depression meta-analyses and includes ICD group ‘Lip, oral cavity and pharynx’ plus laryngeal cancer from ICD group ‘Middle ear, respiratory, intrathoracic organs’.
††Total number of participants does not equal all participants in review as depression prevalence is not known for some cancers and these were not included in comparison.